We aimed to perform an immunohistochemical characterization of a panel of immune biomarkers (CD3, CD4, CD8, CD163, programmed death ligand 1 and programmed death 1) of 30 GBM patients to determine the tumor immune infiltrate and the distribution of the principal immunological markers. This evidence concerns the gene CD8A and neoplasm.